8:00 am Virtual Coffee & Online Registration
8:45 am Chair’s Opening Remarks
OPTIMIZING ANTIGEN SELECTION, PRODUCTION, & PRESENTATION
9:00 am Intradermal Vaccination – Cancer Vaccines
- John Vasiliakos Global Head of MTS Business Development & Senior Research Immunologist, Kindeva
• Microneedles are used to delivery cancer vaccines via the intradermal route. This talk will focus on the rationale for intradermal vaccination and a summary of dendritic cell cancer vaccine trials using Kindeva’s hollow microneedle delivery system.
9:30 am Identification of Novel pHLA Targets for Solid Tumor Targeting with Cancer Vaccines
- Hans-Peter Gerber Chief Scientific Officer, 3T Biosciences
• Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
• Strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders
• Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities
10:00 am Personalized Cancer Vaccines: Technologies to Screen Neoepitope Presentation
- Christopher Rose Senior Scientist & Group Leader, Genentech
• Approaches to enhance presentation of epitopes from candidate neoantigens
• A high throughput targeted mass spectrometry approach for sensitive detection neo-epitope presentation
• Looking toward next generation protein sequencing technologies for neo-epitope discovery
10:30 am Morning Break & Speed Networking
11:15 am ERAP1 Inhibition To Alter Tumor Visibility And Trigger Differentiated T Cell Responses
- Peter Joyce Chief Executive Officer, Grey Wolf Therapeutics
• Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment
• Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface of a cell or tumor
• Grey Wolf ERAP1 inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition
11:45 am Identification Of Patient-Specific T Cell Neoantigens Through Hla-Agnostic Genetic Screens
- Wouter Scheper Senior Postdoctoral Fellow, Netherlands Cancer Institute
• Identification of the T cell-recognized neoantigens in individual cancer patients is complicated by their patient-specific nature.
• We have developed the first genetic neoantigen discovery platform that allows identification of both CD4+ and CD8+ T cell-recognized neoantigens with high sensitivity and across complete HLA genotypes.
• This technology should facilitate the development of personalized neoantigen-based cancer
12:15 pm Whole Framome Cancer Vaccination Through Revolutionizing Neoantigen Detection
- Wigard Kloosterman Chief Scientific Officer, Frame Therapeutics
• Frame Therapeutics focuses on a class of neoantigens, termed Frames, which represent long and completely foreign stretches of amino acids resulting from frame-shift mutations and genomic rearrangements in the tumor genome.
• We show that our FramePro pipeline, combining a variety of sequencing technologies and bioinformatics analysis, can effectively identify all Frames expressed in cancer cells.
12:45 pm Lunch Break & Virtual Networking
CANCER VACCINE CASE STUDIES: mRNA, DNA, VIRAL VECTOR, & PEPTIDE CONTINUED
1:45 pm Rna-Encoded, Extended Half-Life Cytokines In Combination With Rna Vaccination For Synergistic Anti-Tumor Activity
- Lena Kranz Director Cancer Vaccines, BioNTech
• Optimized mRNA platform using lipid nanoparticle technology providing superior immunogenicity
• Proof of concept in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT) targeting nonmutated, shared tumor-associated antigens
• Combination with RNA-encoded, extended half-life cytokines for T cell modulation and enhanced anti-tumor activity
2:15 pm Leveraging Optimized DNA Plasmid Design and Delivery to Treat Glioblastoma Multiforme and Prostate Cancer
- Greg Lu Medical Director, Immuno-Onocology Clinical Development, Inovio Pharmaceuticals,
• Presentation of clinical trial data to show a DNA based cancer vaccine in combination with FLT3 ligand and PD-1 targeting metastatic castration resistant prostate cancer
• Updates on clinical status of a GBM vaccine in combination with cemiplimab (PD-1 inhibitor)
2:45 pm Development of a First-in-class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer
- Alejandro Sepulveda Scientific Director, Head of Cancer Vaccines, Janssen
• Data to show critical understanding of the tumor microenvironment to determine response to immune checkpoint therapy in combination with cancer vaccines
• Identification of VISTA as a potent inhibitory checkpoint that is predominantly expressed on CD68+ macrophages on PDACs, suggesting that VISTA may be a relevant immunotherapy target for effective treatment of patients with pancreatic cancer
3:15 pm Afternoon Break & Speed Networking
3:45 pm Disrupting Glioblastoma: Survaxm Immunotherapy And Surviving Targeting Platforms
- Michael Ciesielski Chief Executive Officer, MimiVax
• SurVaxM is a novel cancer vaccine designed to stimulate an immune response targeting the tumor-specific antigen surviving
• A multi-center, single-arm phase 2a clinical trial of SurVaxM in survivinpositive newly diagnosed glioblastoma (nGBM, NCT02455557) is now complete
• Newly diagnosed glioblastoma patients were followed for safety, 6-month progression-free survival (PFS6), 12-month overall survival (OS12) and immunologic response
• SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in nGBMand has minimal toxicity
• Trial design will be presented. Ongoing work with survivin and its tumor specific biology will be highlighted
4:15 pm Vaccination Against Shared Neoantigens Induced in Recurrent and Future Tumors
- Eli Gilboa Director, Dodson Interdisciplinary Immunotherapy Institute, University of Miami, Miller School of Medicine
• A common set of neoantigens are induced in disseminated tumor lesions by tumor targeted siRNA mediated inhibition of the peptide transporter TAP.
• Vaccination against TAP downregulation induced neoantigens by targeted inhibition of TAP in resident dendritic cells Inhibited tumor growth in transplantable and autochthonous murine tumor models that was superior to vaccination against mutation-derived neoantigens, and was devoid of measurable toxicity.
• Vaccination against induced antigens using one or two broadly applicable chemically synthesized oligonucleotides will also benefit the majority of patients that do not express or express too few mutation derived neoantigens.